Ecromeximab
Ecromeximab
Ecromeximab (pronunciation: /ɛkroʊmɛksɪmæb/) is a monoclonal antibody designed for the treatment of various cancer types.
Etymology
The term "Ecromeximab" is derived from the International Nonproprietary Names (INN), where "E" stands for the target species (equine), "crom" is a stem used for tumor targeting, "xi" indicates a chimeric human-mouse antibody, and "mab" is the suffix for monoclonal antibodies.
Usage
Ecromeximab is used in the treatment of various types of cancers, including melanoma, non-small cell lung cancer, and colorectal cancer. It works by binding to the CD166 antigen, a protein often found on the surface of cancer cells, and triggering an immune response against these cells.
Related Terms
- Monoclonal antibody
- Cancer
- Melanoma
- Non-small cell lung cancer
- Colorectal cancer
- CD166 antigen
- Immune response
External links
- Medical encyclopedia article on Ecromeximab
- Wikipedia's article - Ecromeximab
This WikiMD article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski